Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology... Show more
Twist Bioscience's fiscal fourth-quarter report is a key checkpoint for a synthetic biology company that is still scaling toward consistent profitability. The company writes DNA on silicon, manufacturing custom DNA sequences, synthetic genes, and proteins used across drug discovery, diagnostics, and research. Investors closely track whether its platform can convert growing demand into expanding margins and, ultimately, positive adjusted EBITDA. After years of investment in manufacturing infrastructure, this quarter was expected to show whether the company could cross that profitability threshold while sustaining double-digit revenue growth. The result carries broader significance for the synthetic biology sector, which has faced pressure to demonstrate a clear path from rapid expansion toward sustainable economics.
Twist Bioscience reported fiscal fourth-quarter 2026 revenue of $126.6 million, up 28% from $99.0 million in the prior-year period and modestly above the consensus estimate of roughly $126.35 million. The net loss narrowed to $20.6 million, or $0.32 per diluted share, from $27.1 million, or $0.45 per diluted share, a year earlier, coming in better than the approximately $0.38 loss per share that analysts had projected.
For the full fiscal year, revenue rose 22% to $459.4 million, while the net loss was $130.2 million, or $2.08 per diluted share. The wider full-year loss partly reflects a $48.8 million gain on the sale of a business recorded in fiscal 2025, which flattered the prior-year comparison. Full-year gross margin improved to 52.4% from 50.7%.
On a segment basis, DNA synthesis and protein solutions (DSPS) revenue grew 33% to $61.0 million in the quarter, while next-generation sequencing (NGS) applications revenue grew 24% to $65.7 million. Fourth-quarter adjusted EBITDA turned positive at $2.2 million, a milestone the company has highlighted as a key goal.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring companies like Twist Bioscience, it offers a structured way to surface comparable opportunities across the biotechnology and healthcare landscape.
Heading into the report, sentiment was centered on whether Twist Bioscience could sustain its growth trajectory while finally reaching adjusted EBITDA breakeven. The company's 15 consecutive quarters of sequential revenue growth had built anticipation, but persistent net losses and elevated operating expenses kept some investors cautious. The better-than-expected quarterly loss per share and the first positive adjusted EBITDA print were viewed as encouraging signs, although the wider full-year net loss and rising selling, general, and administrative expenses remain areas of scrutiny. Overall, the results reinforced the narrative of accelerating scale, with attention shifting to whether margin gains can continue into fiscal 2027.
Twist Bioscience guided to fiscal 2027 revenue of $550 million to $560 million, implying continued double-digit growth, and set first-quarter fiscal 2027 revenue guidance of $130 million to $132 million. Investors will be watching whether the company can build on its newly positive adjusted EBITDA and translate scale into more consistent profitability.
Capacity expansion is a central theme. Management is adding another characterization lab at its Oregon facility and expanding DNA, protein, and characterization workflows to support larger customer programs. Executing these investments without eroding the recent margin gains will be an important test.
Demand signals also matter. The company highlighted AI-enabled drug discovery as one of its fastest-growing product groups, along with momentum in next-generation sequencing (NGS) applications, including the recently launched MRD (molecular residual disease) Express product. Sustained customer adoption across both DSPS and NGS segments will be key to hitting guidance.
Finally, investors should monitor operating expense discipline and cash management. With roughly $582 million in cash and short-term investments after a recent capital raise, the company has flexibility, but the pace of reinvestment versus the path toward sustained profitability will likely shape sentiment in the quarters ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology